Compare Cassava Sciences Inc (FLNA) vs Goodyear Tire & Rubber Co (GT) Price & Performance

Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.

The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.

Goodyear Tire & Rubber (GT) trades at $6.66, up 0.3% with neutral technical signals. The stock shows mixed fundamentals with attractive valuation ratios (P/E 4.69, P/B 0.64) but negative profitability (ROE -52.56%, net margin -11.64%). Recent Q1 2026 earnings beat estimates despite a loss, while the company transitions to S&P SmallCap 600. Cash flow improved in 2025 with $46M net inflow, though revenue declined to $18.28B.

Outlook remains challenging with declining revenue and negative margins, though deep value metrics and analyst consensus target of $8.75 suggest upside potential. Key risks include persistent operational headwinds, weak tire demand, and high debt levels. The Goodyear Forward program and lunar tire contract provide strategic catalysts amid competitive pressures.